Lartesertib

DB19045InvestigationalSmall molecule

Lartesertib is under investigation in clinical trial NCT06433219 (Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (Ddriver EOC 302)).

Mechanism: Pharmacologically active on Serine-protein kinase ATM
Curator reviewed
Formula / weight: C₂₃H₂₁FN₆O₃ · 448.458 g/mol (avg)
Also known as: 2H-Imidazo[4,5-c]quinolin-2-one, 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-, (1S)- · 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-2h-imidazo(4,5-c)quinolin-2-one
Code names: M-4076

Resolves to

Compound

UNIIKL7B6D38VCCAS2495096-26-7

Structure

InChIKeyWNEFOSMCGCLLJU-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1C1=CN(C)N=C1C)C1=C(C=N2)N(C)C(=O)N1C1=C(F)C=NC=C1OC

Targets

Q13315ATM

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lartesertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account